Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Study to Determine the Safety, Immunogenicity and Efficacy of the Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104

Next Previous
X
Search
Trial Profile

Phase I/II Study to Determine the Safety, Immunogenicity and Efficacy of the Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ISA 104 (Primary) ; Adjuvants
  • Indications Hepatitis B
  • Focus Adverse reactions; First in man
  • Acronyms HEB-PEP

    • Most Recent Events

    • 31 Aug 2023 According to a ISA Pharmaceuticals media release, Dr. Sonja Buschow is the Principal Investigators of the study.
    • 31 Aug 2023 According to a ISA Pharmaceuticals media release, the study is The study is conducted in collaboration with investigators of the Gastroenterology & Hepatology department of the Erasmus MC in Rotterdam, The Netherlands.
    • 31 Aug 2023 According to a ISA Pharmaceuticals media release, first patient has been dosed in this trial and dosing took place at the Liver Unit of the Erasmus Medical Center in Rotterdam.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top